| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 22,178 | 22,882 | ||
| General and administrative | 5,728 | 5,731 | ||
| Total operating expenses | 27,906 | 28,613 | ||
| Total operating loss | -27,906 | -28,613 | ||
| Interest income, including amortization and accretion income | 1,815 | 1,678 | ||
| Other expense | -13 | -36 | ||
| Total other income | 1,802 | 1,642 | ||
| Loss before income taxes | -26,104 | -26,971 | ||
| Income tax provision, net | 26 | 48 | ||
| Net loss | -26,130 | -27,019 | ||
| Unrealized gain (loss) on marketable securities | 57 | -88 | ||
| Currency translation adjustment | -13 | 8 | ||
| Total other comprehensive gain (loss) | 44 | -80 | ||
| Total comprehensive loss | -26,086 | -27,099 | ||
| Net loss per common share - basic | -0.4 | -0.47 | ||
| Net loss per common share - diluted | -0.4 | -0.47 | ||
| Weighted average common stock outstanding - basic | 65,936,672 | 58,015,718 | ||
| Weighted average common stock outstanding - diluted | 65,936,672 | 58,015,718 | ||
Aura Biosciences, Inc. (AURA)
Aura Biosciences, Inc. (AURA)